Results of 2026 Annual General Meeting 23 October 2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to advise that shareholders of the Company passed all Resolutions by poll at the Annual General Meeting held today at 2:00pm (AEST). In accordance with ASX Listing...
Results of Meeting
Filed with ASX · · 3 pages · English
Release
In the deck
Earlier from LTR Pharma
- AGM Presentation
- SPONTAN to be Evaluated in Pulmonary Arterial Hypertension
- SPONTAN passes 2,000 dispensed units in Australia
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- Investor Webinar Presentation
Later from LTR Pharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- Nick Bell Joins LTR Pharma as Strategic Adviser
- Notification regarding unquoted securities - LTP
- Change of Director's Interest Notice - M McGuire
- Change of Director's Interest Notice - J Chick
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma